 |  |  |  |  |  |
 |
 |
| Copyright 2006-2010 Abiant, Inc. |
| Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030 |
| New and Events... |
Abiant Presents Advances at ICAD 2010
GRAYSLAKE, ILLINOIS - - July 12, 2010 - - Abiant was selected to present a poster at the 2010
International Conference on Alzheimer's Disease (ICAD) on July 12, 2010. The poster was titled
"Regional Cerebral Glucose Metabolism provides a highly sensitive and specific marker of Alzheimer’s
Disease, Frontotemporal Dementia, and prodromal states, and correlates with declines in
cerebrospinal fluid Abeta42 levels in cognitively normal subjects", and may be viewed here.
By precisely measuring changes in glucose metabolism using Positron Emission Tomography scans,
Abiant was able to achieve high levels of sensitivity, specificity, and overall accuracy in discriminating
Normals, Alzheimer's Disease patients, and those with Frontotemporal Dementia. In addition, Abiant
found that glucose metabolism decreased with the earliest changes noted in the cerebrospinal fluid
concentrations of Abeta42, which is associated with the subsequent deposition of amyloid plaque in the
brains of these patients.
ICAD, sponsored by the Alzheimer's Association (www.alz.org), is one of the world's largest and premier
conferences on the care, diagnosis, and treatment of Alzheimer's Disease. The conference took place
from July 10 - 16 in Honolulu, Hawaii, and was attended by leaders in the Alzheimer's Disease,
neuroimaging, and pharmaceutical development fields.
ADNI is a $60 million, 5-year public-private partnership to test whether serial magnetic resonance
imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild cognitive
impairment (MCI) and early Alzheimer’s disease (AD). Additional information can be found at the ADNI
website.
The work presented in Abiant's poster is part of the company's ongoing progress toward the
development of imaging measures that can be applied in clinical trials of candidate drugs, and to
achieve the early, accurate diagnosis of patients who are on a path to dementia.
Abiant, Inc.
Abiant, Inc. uses proprietary image analysis methods and software to provide sensitive biomarkers of
drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, is intended to accelerate or reduce risk of decision making in
both drug development and disease treatment.
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
GRAYSLAKE, ILLINOIS - - July 12, 2010 - - Abiant was selected to present a poster at the 2010
International Conference on Alzheimer's Disease (ICAD) on July 12, 2010. The poster was titled
"Regional Cerebral Glucose Metabolism provides a highly sensitive and specific marker of Alzheimer’s
Disease, Frontotemporal Dementia, and prodromal states, and correlates with declines in
cerebrospinal fluid Abeta42 levels in cognitively normal subjects", and may be viewed here.
By precisely measuring changes in glucose metabolism using Positron Emission Tomography scans,
Abiant was able to achieve high levels of sensitivity, specificity, and overall accuracy in discriminating
Normals, Alzheimer's Disease patients, and those with Frontotemporal Dementia. In addition, Abiant
found that glucose metabolism decreased with the earliest changes noted in the cerebrospinal fluid
concentrations of Abeta42, which is associated with the subsequent deposition of amyloid plaque in the
brains of these patients.
ICAD, sponsored by the Alzheimer's Association (www.alz.org), is one of the world's largest and premier
conferences on the care, diagnosis, and treatment of Alzheimer's Disease. The conference took place
from July 10 - 16 in Honolulu, Hawaii, and was attended by leaders in the Alzheimer's Disease,
neuroimaging, and pharmaceutical development fields.
ADNI is a $60 million, 5-year public-private partnership to test whether serial magnetic resonance
imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild cognitive
impairment (MCI) and early Alzheimer’s disease (AD). Additional information can be found at the ADNI
website.
The work presented in Abiant's poster is part of the company's ongoing progress toward the
development of imaging measures that can be applied in clinical trials of candidate drugs, and to
achieve the early, accurate diagnosis of patients who are on a path to dementia.
Abiant, Inc.
Abiant, Inc. uses proprietary image analysis methods and software to provide sensitive biomarkers of
drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, is intended to accelerate or reduce risk of decision making in
both drug development and disease treatment.
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
Abiant News